RL
Therapeutic Areas
ARS Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| neffy® (epinephrine nasal spray) | Emergency treatment of severe allergic reactions (Type I), including anaphylaxis | Approved |
| Intranasal Epinephrine | Acute flares of chronic spontaneous urticaria (CSU) | Preclinical |
Leadership Team at ARS Pharmaceuticals
ST
Sarina Tanimoto, M.D., M.B.A.
Chief Medical Officer
EK
Eric Karas
Chief Commercial Officer
KS
Kathleen Scott
Chief Financial Officer
PS
Pratik Shah, Ph.D.
Chair of the Board of Directors
PK
Peter Kolchinsky, Ph.D.
Director
RD
Rajeev Dadoo, Ph.D.
Director
BS
Brenton Saunders
Director
PS
Phillip Schneider
Director
MK
Michael Kelly
Director
SI
Saqib Islam, J.D.
Director